Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

1125380

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Health Service Products (Provision and Disclosure of Information) Regulations 2018, how many times his Department has sought information relating to bespoke medicines from small producers with an annual NHS turnover of less than £5 million; and whether he plans to make an assessment on the potential merits of requiring all small producers to automatically supply quarterly information on those medicines.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	252063
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Health Service Products (Provision and Disclosure of Information) Regulations 2018 (the Regulations) prescribe when manufacturers, importers and wholesalers of special medicinal products are required to provide information. Since the Regulations entered into force, quarterly information has been received in November 2018 and February 2019 and information is again due at the end of May 2019. The requirement to provide quarterly sales, purchase and volume information about special medicinal products already applies to all manufacturers, importers and wholesalers regardless of their size. Therefore, there is no need for an assessment on the potential merits of requiring all small producers to automatically supply quarterly information.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 252064 question first answered 13/05/2019 15:40:15 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1125381

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Health Service Products (Provision and Disclosure of Information) Regulations 2018, what criteria his Department uses to decide on which small producers to seek information from.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	252064
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Health Service Products (Provision and Disclosure of Information) Regulations 2018 (the Regulations) prescribe when manufacturers, importers and wholesalers of special medicinal products are required to provide information. Since the Regulations entered into force, quarterly information has been received in November 2018 and February 2019 and information is again due at the end of May 2019. The requirement to provide quarterly sales, purchase and volume information about special medicinal products already applies to all manufacturers, importers and wholesalers regardless of their size. Therefore, there is no need for an assessment on the potential merits of requiring all small producers to automatically supply quarterly information.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 252063 question first answered 13/05/2019 15:40:15 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1125382

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Health Service Products (Provision and Disclosure of Information) Regulations 2018, what steps he is taking to ensure that (a) wholesalers and (b) importers are providing his Department with information on medicines.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	252065
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Department is undertaking an exercise to ensure that all companies that are required to provide quarterly information under the Health Service Products (Provision and Disclosure of Information) Regulations 2018 (the Regulations) are doing so. Where they are not, the Department will consider taking the appropriate action provided for in the Regulations.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 13/05/2019 15:39:14 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1125383

	registered interest
	date	08/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when he plans to use the powers set out in the Health Service Products (Provision and Disclosure of Information) Regulations 2018 to seek information on the special health service medicine selected yy medical professional bodies.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	252066
	answer	answer is ministerial correction date of answer 13/05/2019 answer text <p>The Department selects medicines to be included in the quarterly collection of information on special medicinal products based on the level of prescribing. If medical professional bodies have selected special medicinal products that they believe should be included with a reimbursement price in Part VIIIB of the Drug Tariff then the Department will consider including those products in the quarterly collection, but only if those products are prescribed in primary care. If products are not prescribed in primary care then there is no sales, purchase and volume information for special medicinal products supplied to primary care that can be provided by suppliers in the quarterly information collection.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 13/05/2019 16:08:08 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1140407

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department is taking to tackle the overcharging of medicines to the NHS.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	279026
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>The costs of branded medicines are controlled by the statutory and voluntary schemes for branded medicines. Under those schemes, any price increase needs to be agreed by the Department. For generic medicines, the Department encourages competition between suppliers to drive prices down. This generally works well but there are instances where there is no or not enough competition and prices appear unreasonably high. Section 262 of the National Health Service Act 2006 enables the Secretary of State to limit the price of any medicine not covered by the voluntary scheme for branded medicines. The Department is preparing a public consultation on the use of this power for generic medicines. The Health Service Products (Provision and Disclosure of Information) Regulations 2018 support the powers in the National Health Service Act 2006 by enabling the Secretary of State to require suppliers to provide information about their products including information about the cost of manufacturing those products.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279028 question first answered 23/07/2019 16:46:17 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1140411

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether his Department will use the Health Service Products (Provision and Disclosure of Information) Regulations 2018 to prevent price inflation of medicines.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	279028
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>The costs of branded medicines are controlled by the statutory and voluntary schemes for branded medicines. Under those schemes, any price increase needs to be agreed by the Department. For generic medicines, the Department encourages competition between suppliers to drive prices down. This generally works well but there are instances where there is no or not enough competition and prices appear unreasonably high. Section 262 of the National Health Service Act 2006 enables the Secretary of State to limit the price of any medicine not covered by the voluntary scheme for branded medicines. The Department is preparing a public consultation on the use of this power for generic medicines. The Health Service Products (Provision and Disclosure of Information) Regulations 2018 support the powers in the National Health Service Act 2006 by enabling the Secretary of State to require suppliers to provide information about their products including information about the cost of manufacturing those products.</p> answering member constituency South Ribble answering member printed Seema Kennedy grouped question UIN 279026 question first answered 23/07/2019 16:46:17 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris

1140412

	registered interest
	date	18/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps he is taking to tackle the promotion of red listed drugs to non-specialist healthcare professionals by pharmaceutical companies.
	tabling member constituency	Newton Abbot
	tabling member printed	Anne Marie Morris
	uin	279029
	answer	answer is ministerial correction date of answer 23/07/2019 answer text <p>The Medicines and Healthcare products Regulatory Agency investigates, or appropriately refers to another medicines self-regulatory body, complaints from any source about medicines advertising in relation to compliance with United Kingdom legislation.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 23/07/2019 16:39:00 answering member 4455 label Biography information for Seema Kennedy
	tabling member	4249 label Biography information for Anne Marie Morris